SCHEMBL30748839

SCHEMBL30748839

NC(=O)c1nccc(Nc2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.50
KCNH2 Q12809 1/20 0.50
AURKA O14965 5/20 0.49
ROCK1 Q13464 3/20 0.49
SCN5A Q14524 1/20 0.48
AURKB Q96GD4 1/20 0.47
SYK P43405 1/20 0.47
MAPK8 P45983 3/20 0.46
BCL6 P41182 1/20 0.46
PARP10 Q53GL7 1/20 0.45
ERBB2 P04626 1/20 0.45
MAPK10 P53779 1/20 0.44
PLK1 P53350 1/20 0.44
IKBKB O14920 2/20 0.44
CHEK1 O14757 1/20 0.43
NPC1 O15118 1/20 0.43
PDPK1 O15530 1/20 0.43
CHEK2 O96017 1/20 0.43
PRKCG P05129 1/20 0.43
CDK1 P06493 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748867 0.89 AURKA (0.52) SCN9AKCNH2AURKAROCK1SCN5A
SCHEMBL29448928 0.87 AURKA (0.60) AURKAROCK1AURKBMAPK8BCL6
SCHEMBL31691345 0.86 ROCK1 (0.51) SCN9AKCNH2AURKAROCK1SCN5A
SCHEMBL15522350 0.76 SCN9A (0.59) SCN9AKCNH2AURKAROCK1SCN5A
SCHEMBL30748744 0.76 ERBB2 (0.50) SCN9AKCNH2AURKAROCK1SCN5A
SCHEMBL3236170 0.75 AURKA (0.61) AURKAROCK1AURKBMAPK8BCL6
SCHEMBL30748746 0.73 ABCG2 (0.51) SCN9AKCNH2AURKAROCK1SCN5A
SCHEMBL30748940 0.73 SCN9A (0.49) SCN9AKCNH2AURKAROCK1SCN5A
SCHEMBL25884869 0.73 AURKA (0.56) AURKAROCK1AURKBMAPK8BCL6
SCHEMBL28103574 0.72 AURKA (0.58) AURKAAURKBMAPK8PLK1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT SCN9A 4230/4885KCNH2 4554/4885AURKA 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.